GH Research (NASDAQ:GHRS) Stock Price Up 0.6% – Time to Buy?

GH Research PLC (NASDAQ:GHRS) shares were up 0.6% on Tuesday . The stock traded as high as $8.10 and last traded at $8.05. Approximately 13,641 shares traded hands during trading, a decline of 83% from the average daily volume of 79,417 shares. The stock had previously closed at $8.00.

Wall Street Analyst Weigh In

Several research firms recently issued reports on GHRS. JMP Securities reaffirmed a “market outperform” rating and issued a $39.00 price objective on shares of GH Research in a research report on Wednesday, September 4th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of GH Research in a report on Thursday, September 5th.

GH Research Trading Up 0.9 %

The firm has a market cap of $419.88 million, a P/E ratio of -12.01 and a beta of 0.74. The stock has a 50 day simple moving average of $7.96 and a 200-day simple moving average of $10.50.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.03. As a group, equities analysts forecast that GH Research PLC will post -0.85 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GH Research

A hedge fund recently raised its stake in GH Research stock. Lynx1 Capital Management LP increased its holdings in GH Research PLC (NASDAQ:GHRS) by 19.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 3,966,726 shares of the company’s stock after acquiring an additional 656,163 shares during the period. GH Research makes up about 16.7% of Lynx1 Capital Management LP’s holdings, making the stock its 3rd largest holding. Lynx1 Capital Management LP owned approximately 7.62% of GH Research worth $46,252,000 as of its most recent SEC filing. 56.90% of the stock is owned by institutional investors and hedge funds.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).